Literature DB >> 16508012

Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis.

Kathryn A O'Donnell1, Duonan Yu, Karen I Zeller, Jung-Whan Kim, Frederick Racke, Andrei Thomas-Tikhonenko, Chi V Dang.   

Abstract

Overexpression of transferrin receptor 1 (TFRC1), a major mediator of iron uptake in mammalian cells, is a common feature of human malignancies. Therapeutic strategies designed to interfere with tumor iron metabolism have targeted TFRC1. The c-Myc oncogenic transcription factor stimulates proliferation and growth by activating thousands of target genes. Here we demonstrate that TFRC1 is a critical downstream target of c-Myc. Using in vitro and in vivo models of B-cell lymphoma, we show that TFRC1 expression is activated by c-Myc. Chromatin immunoprecipitation experiments reveal that c-Myc directly binds a conserved region of TFRC1. In light of these findings, we sought to determine whether TFRC1 is required for c-Myc-mediated cellular proliferation and cell size control. TFRC1 inhibition decreases cellular proliferation and results in G1 arrest without affecting cell size. Consistent with these findings, expression profiling reveals that TFRC1 depletion alters expression of genes that regulate the cell cycle. Furthermore, enforced TFRC1 expression confers a growth advantage to cells and significantly enhances the rate of c-Myc-mediated tumor formation in vivo. These findings provide a molecular basis for increased TFRC1 expression in human tumors, illuminate the role of TFRC1 in the c-Myc target gene network, and support strategies that target TFRC1 for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16508012      PMCID: PMC1430295          DOI: 10.1128/MCB.26.6.2373-2386.2006

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  64 in total

1.  Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes.

Authors:  Izidore S Lossos; Ash A Alizadeh; Maximilian Diehn; Roger Warnke; Yvonne Thorstenson; Peter J Oefner; Patrick O Brown; David Botstein; Ronald Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-19       Impact factor: 11.205

Review 2.  Transcriptional regulation and transformation by Myc proteins.

Authors:  Sovana Adhikary; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2005-08       Impact factor: 94.444

3.  Large-scale analysis of the human and mouse transcriptomes.

Authors:  Andrew I Su; Michael P Cooke; Keith A Ching; Yaron Hakak; John R Walker; Tim Wiltshire; Anthony P Orth; Raquel G Vega; Lisa M Sapinoso; Aziz Moqrich; Ardem Patapoutian; Garret M Hampton; Peter G Schultz; John B Hogenesch
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

4.  The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation.

Authors:  Diane R Wonsey; Karen I Zeller; Chi V Dang
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

5.  A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.

Authors:  Duonan Yu; Andrei Thomas-Tikhonenko
Journal:  Oncogene       Date:  2002-03-14       Impact factor: 9.867

6.  Characterization of nucleophosmin (B23) as a Myc target by scanning chromatin immunoprecipitation.

Authors:  K I Zeller; T J Haggerty; J F Barrett; Q Guo; D R Wonsey; C V Dang
Journal:  J Biol Chem       Date:  2001-10-16       Impact factor: 5.157

7.  A functional screen for Myc-responsive genes reveals serine hydroxymethyltransferase, a major source of the one-carbon unit for cell metabolism.

Authors:  Mikhail A Nikiforov; Sanjay Chandriani; Brenda O'Connell; Oleksi Petrenko; Iulia Kotenko; Andrew Beavis; John M Sedivy; Michael D Cole
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

Review 8.  Iron chelators as therapeutic agents for the treatment of cancer.

Authors:  D R Richardson
Journal:  Crit Rev Oncol Hematol       Date:  2002-06       Impact factor: 6.312

Review 9.  c-MYC: more than just a matter of life and death.

Authors:  Stella Pelengaris; Mike Khan; Gerard Evan
Journal:  Nat Rev Cancer       Date:  2002-10       Impact factor: 60.716

10.  c-Myc represses the murine Nramp1 promoter.

Authors:  H Bowen; T E Biggs; S T Baker; E Phillips; V H Perry; D A Mann; C H Barton
Journal:  Biochem Soc Trans       Date:  2002-08       Impact factor: 5.407

View more
  94 in total

1.  MicroRNA-320 induces neurite outgrowth by targeting ARPP-19.

Authors:  Robin E White; Rona G Giffard
Journal:  Neuroreport       Date:  2012-07-11       Impact factor: 1.837

2.  18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers.

Authors:  Nicolaos Palaskas; Steven M Larson; Nikolaus Schultz; Evangelia Komisopoulou; Justin Wong; Dan Rohle; Carl Campos; Nicolas Yannuzzi; Joseph R Osborne; Irina Linkov; Edward R Kastenhuber; Richard Taschereau; Seema B Plaisier; Chris Tran; Adriana Heguy; Hong Wu; Chris Sander; Michael E Phelps; Cameron Brennan; Elisa Port; Jason T Huse; Thomas G Graeber; Ingo K Mellinghoff
Journal:  Cancer Res       Date:  2011-06-06       Impact factor: 12.701

3.  Smap1 deficiency perturbs receptor trafficking and predisposes mice to myelodysplasia.

Authors:  Shunsuke Kon; Naoko Minegishi; Kenji Tanabe; Toshio Watanabe; Tomo Funaki; Won Fen Wong; Daisuke Sakamoto; Yudai Higuchi; Hiroshi Kiyonari; Katsutoshi Asano; Yoichiro Iwakura; Manabu Fukumoto; Motomi Osato; Masashi Sanada; Seishi Ogawa; Takuro Nakamura; Masanobu Satake
Journal:  J Clin Invest       Date:  2013-02-22       Impact factor: 14.808

4.  Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.

Authors:  Erick Riquelme; Milind B Suraokar; Jaime Rodriguez; Barbara Mino; Heather Y Lin; David C Rice; Anne Tsao; Ignacio I Wistuba
Journal:  J Thorac Oncol       Date:  2014-07       Impact factor: 15.609

Review 5.  Transferrin receptor 1 in cancer: a new sight for cancer therapy.

Authors:  Ying Shen; Xin Li; Dandan Dong; Bin Zhang; Yanru Xue; Peng Shang
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

Review 6.  MYC, Metabolism, and Cancer.

Authors:  Zachary E Stine; Zandra E Walton; Brian J Altman; Annie L Hsieh; Chi V Dang
Journal:  Cancer Discov       Date:  2015-09-17       Impact factor: 39.397

7.  Regulation of ferroptotic cancer cell death by GPX4.

Authors:  Wan Seok Yang; Rohitha SriRamaratnam; Matthew E Welsch; Kenichi Shimada; Rachid Skouta; Vasanthi S Viswanathan; Jaime H Cheah; Paul A Clemons; Alykhan F Shamji; Clary B Clish; Lewis M Brown; Albert W Girotti; Virginia W Cornish; Stuart L Schreiber; Brent R Stockwell
Journal:  Cell       Date:  2014-01-16       Impact factor: 41.582

8.  Time-dependent c-Myc transactomes mapped by Array-based nuclear run-on reveal transcriptional modules in human B cells.

Authors:  Jinshui Fan; Karen Zeller; Yu-Chi Chen; Tonya Watkins; Kathleen C Barnes; Kevin G Becker; Chi V Dang; Chris Cheadle
Journal:  PLoS One       Date:  2010-03-15       Impact factor: 3.240

9.  Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693.

Authors:  Rakesh Kumar; Stephen J Blakemore; Catherine E Ellis; Emanuel F Petricoin; Dexter Pratt; Michael Macoritto; Andrea L Matthews; Joseph J Loureiro; Keith Elliston
Journal:  BMC Genomics       Date:  2010-07-06       Impact factor: 3.969

10.  Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lymphocytes.

Authors:  David K Finlay; Linda V Sinclair; Carmen Feijoo; Caryll M Waugh; Thijs J Hagenbeek; Hergen Spits; Doreen A Cantrell
Journal:  J Exp Med       Date:  2009-10-05       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.